Press Releases

SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 2, 2011 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the completion of a clinical study that measured lorcaserin...

Woodcliff Lake, NJ, July 29, 2011 - Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File letter in response to the company's New Drug...

Tokyo, Japan, July 19, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") today announced the launch of its novel anticancer agent Halaven in Japan for the...

Woodcliff Lake, NJ, July 13, 2011 - Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking...

Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic...